11 – 20 of 121
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Modulation of pTau181 by Glypican-1-Derived Heparan Sulfate in Human Neural Progenitor Cells and ApoE4-Expressing Induced Neurons
- Contribution to journal › Article
- 2024
-
Mark
Survey among experts on the future role of tau-PET in clinical practice and trials
- Contribution to journal › Article
-
Mark
Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo
- Contribution to journal › Article
-
Mark
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
- Contribution to journal › Article
-
Mark
Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions
- Contribution to journal › Article
-
Mark
Association of quantitative histopathology measurements with antemortem medial temporal lobe cortical thickness in the Alzheimer’s disease continuum
- Contribution to journal › Article
-
Mark
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
- Contribution to journal › Article
-
Mark
Interplay between glypican-1, amyloid-β and tau phosphorylation in human neural stem cells
- Contribution to journal › Article
-
Mark
Plasma N-terminal containing tau fragments (NTA-tau) : a biomarker of tau deposition in Alzheimer’s Disease
- Contribution to journal › Article
-
Mark
Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum
- Contribution to journal › Article
